Supplementary Figure 6. Extensively acetylated peaks are preferable targets of butyrate-induced hypo-acetylation, but in a selective manner. (A) Gene expression (RPKM) of LAIR, LCP2, LAT and LAT2 in human mast cells derived from two different donors treated with 5mM Butyrate for 24 h. (B) Genomic browser view of representative examples of unaffected or (transient) hyper-acetylation at established acetylation peaks. (C) Venn diagram comparing the 1203 hypo-acetylated peaks after 3 hours of butyrate treatment with the top 500 most acetylated peaks in the mast cell epigenome. (D) Venn diagram comparing the 1203 hypo-acetylated peaks after 3 hours of butyrate treatment with the top 5000 most acetylated peaks in the mast cell genome.